ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Drug toxicity"

  • Abstract Number: 0747 • ACR Convergence 2024

    Clofutriben to Improve the Benefit-Risk Profile of Prednisolone in Patients with Polymyalgia Rheumatica

    FRANK HARTMUT DR. BUTTGEREIT1, Andrea Everding2, Ioana Andreica3, Herbert Kellner4, Florian Schuch5, Tonya K Marmon6, Frank S Czerwiec7, Ketan Desai8 and David A Katz9, 1Charité University Medicine Berlin, Berlin, Germany, 2Hamburger Rheuma Forschungszentrum II, Hamburg, Germany, 3Rheumazentrum Ruhrgebiet, Bochum, Germany, 4Schwerpunktpraxis f�r Rheumatologie und Gastroenterologie, Munich, Germany, 5PGRN, Erlangen, Germany, 6Marmon Biostatistics, Seattle, WA, 7Sparrow Pharmaceuticals, Portand, OR, 8IMC, Easton, PA, 9Sparrow Pharmaceuticals, Portland, OR

    Background/Purpose: 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) differentially regulates intracellular glucocorticoid levels in the immune system and glucocorticoid toxicity target organs. Clofutriben is a potent HSD-1…
  • Abstract Number: 2178 • ACR Convergence 2024

    Evaluating the Non-Inferiority of Mycophenolate Mofetil Compared to Methotrexate in Treating Juvenile Localized Scleroderma

    Elena DeRosas1, Haley Havrilla2 and Kathryn Torok3, 1University of Pittsburgh, Pittsburgh, PA, 2Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 3Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: Methotrexate (MTX) has historically been used as first-line therapy for juvenile localized scleroderma (jLS), but tolerability often limit compliance. Recent evidence from case series…
  • Abstract Number: 0913 • ACR Convergence 2024

    The Association Between PTPN2 and Leukopenia in New Users of Azathioprine

    Puran Nepal1, Laura L. Daniel2, Jacy Zanussi2, Alyson L. Dickson3, Wei-Qi Wei3, Adriana M. Hung4, Nancy J. Cox3, Vivian K. Kawai3, Jonathan D. Mosley3, C. Michael Stein3, QiPing Feng3, Ge Liu3, Ran Tao3 and Cecilia P. Chung2, 1Vanderbilt University Medical Center, Vanderbilt, TN, 2University of Miami, Miami, FL, 3Vanderbilt University Medical Center, Nashville, TN, 4Veterans Administration Tennessee Valley Healthcare System, Nashville, TN

    Background/Purpose: Leukopenia is a common dose-dependent side effect of azathioprine and often results in discontinuation of the drug. Variants in TPMT and NUDT15 have been…
  • Abstract Number: 2199 • ACR Convergence 2024

    Mycobacterial Infection and Renal and Bladder Malignancy in 2 IFNopathy Patients on High Doses of JAK Inhibitors

    Sara Alehashemi1, Kader Cetin Gedik2, Cassandra Calabrese3, Sherry Nguyen4, Alexi Baumgardner4, Katsiaryna Uss4, Kip Friend4, Ariane Soldatos5, Adriana Almeida de Jesus6 and Raphaela Goldbach-Mansky7, 1NIH/NIAID/TADS, Potomac, MD, 2Translational Autoinflammatory Diseases section (TADS), LCIM, NIAID, NIH, Pittsburgh, PA, 3Cleveland Clinic Foundation, Cleveland Heights, OH, 4Translational Autoinflammatory Diseases section (TADS), LCIM, NIAID, NIH, Bethesda, MD, 5NINDS/NIH, Bethesda, MD, 6NIAID, NIH, Silver Spring, MD, 7Translational Autoinflammatory Diseases section (TADS), LCIM, NIAID, NIH, Potomac, MD

    Background/Purpose: Autoinflammatory Type I Interferonopathies (IFNopathies) include STINGopathies (e.g., SAVI and COPA syndrome), proteasomopathies (e.g., CANDLE/Proteasome associated autoinflammatory syndrome (PRAAS), and oligonucleotidopathies (e.g., AGS: Aicardi-Goutières…
  • Abstract Number: 0914 • ACR Convergence 2024

    RAB19 and Azathioprine-Associated Pancreatic Injury in Patients Taking Azathioprine

    Shailja C. Shah1, Tyler S. Reese2, Laura L. Daniel3, Puran Nepal4, Jacy Zanussi3, Alyson L. Dickson2, Ran Tao2, Adriana M. Hung5, Wei-Qi Wei2, C. Michael Stein2, QiPing Feng2 and Cecilia P. Chung3, 1University of California, San Diego, San Diego, CA, 2Vanderbilt University Medical Center, Nashville, TN, 3University of Miami, Miami, FL, 4Vanderbilt University Medical Center, Vanderbilt, TN, 5Veterans Administration Tennessee Valley Healthcare System, Nashville, TN

    Background/Purpose: Pancreatitis is a rare, but potentially life-threatening adverse event associated with the use of azathioprine. Prior studies have found an association between the HLA…
  • Abstract Number: 2429 • ACR Convergence 2024

    Impact of Hydroxychloroquine Level on ECG QTC Interval in Patients with Rheumatic Systemic Autoimmune Diseases: A Real-life Study

    Carmen Raya-Santos1, José Rosas-Gómez de Salazar2, Mariana Marco3, Ana Pons-Bas3, Rocío Gallego Campuzano4, Juan Carlos Cortes4, Lara Pons-Canet3, Maruan Shalabi3, José Miguel Senabre3, José Antonio Bernal5, Gregorio Santos-Soler6, Xavier Barber7 and Jose Alberto Garcia Gomez7, 1Hospital Marina Baixa, Villajoyosa (Alicante), Spain, 2Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, 3Hospital Marina Baixa, Villajoyosa, Spain, 4Hospital Marina Baixa, Villajoyosa, Comunidad Valenciana, Spain, 5Hospital Marina Baixa (Villajoyosa), Alicante, Spain, 6Hospital Marina Baixa, Villajoyosa, 7Miguel Hernandez University, Villajoyosa, Spain

    Background/Purpose: The administration of hydroxychloroquine-sulphate (HCQ) can lead to the risk of QTc prolongation and cardiac arrhythmias. We evaluated the HCQ concentration and the incidence…
  • Abstract Number: 1115 • ACR Convergence 2024

    Rheumatic Disease Patients: Assessment of Hydroxychloroquine’s Effects on QTc Intervals with Weight Based Dosing (RAISE-QT) Study

    Joseph Azzam1, Johny Fares1, nithin Pusapati1, Swamy Venuturupalli2 and Daniel Wallace3, 1Cedars Sinai, Los Angeles, 2Attune Health, Beverly Hills, CA, 3Cedars Sinai Medical Center, Studio City, CA

    Background/Purpose: The primary objective was to investigate subjects with rheumatic disease (Systemic Lupus Erythematosus (SLE), Sjogrens disease (SjD), and Rheumatoid Arthritis (RA)) who initiated HCQ…
  • Abstract Number: 2457 • ACR Convergence 2024

    Polypharmacy, Drug-drug Interactions, and Adverse Drug Reactions Among Systemic Sclerosis Patients: A Cross-sectional Risk Factor Study

    Sara Boukhlal1, Laurent Chouchana2, Malika Saadi3, marion Casadevall1, Pascal cohen4, bertrand Dunogue5, Anne Murarasu1, Alexis Régent6, Luc Mouthon5 and Benjamin Chaigne7, 1AP HP, paris, France, 2Cochin, Paris, France, 3Cardiology Department - Cochin Hospital, Paris, France, 4National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, 5Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 6National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 7Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France

    Background/Purpose: Polypharmacy, drug-drug interactions (DDI) and related adverse drug reaction (ADR) are understudied in SSc. The aim of this work was to determine the prevalence…
  • Abstract Number: 0152 • ACR Convergence 2024

    Hydroxychloroquine and Chloroquine Retinopathy in Hispanic Patients with Rheumatic Diseases

    Janett Riega Torres1, Karina Palomo-Arnaud2, Gabriel Figueroa-Parra1, Fernando Morales Wong1, Jesús Hernán González Cortés1, Jesus Mohamed Hamsho1, Jorge Esquivel-Valerio1, Dionicio Galarza-Delgado3 and Karim Mohamed Noriega1, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, 3UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Antimalarial drugs like hydroxychloroquine (HCQ) and chloroquine (CQ) are among the most frequently prescribed medications in Rheumatology.  Retinal toxicity is an unwanted side effect…
  • Abstract Number: 1124 • ACR Convergence 2024

    Impact of Genetic Predisposition for Type 2 Diabetes in Plasma Glucose Levels After the Administration of a High Dose of Systemic Glucocorticoids

    Xiaodi Ruan1, Michael Williams2, Gul Karakoc1, Elizabeth McNeer1, Leena Choi1, Jonathan D. Mosley1, C. Michael Stein1 and Vivian K. Kawai1, 1Vanderbilt University Medical Center, Nashville, TN, 2VUMC, Nashville, TN

    Background/Purpose: Glucocorticoids (GCs) are potent anti-inflammatory drugs that are commonly prescribed, particularly for rheumatic and immunologic conditions. Hyperglycemia is an important adverse effect and occurs…
  • Abstract Number: 2496 • ACR Convergence 2024

    Clinical Features and Outcomes of Hydralazine-associated Vasculitis: A Case-Control Study

    Elif Ediboglu1, Samuel Falde1, Misbah Baqir1, Rodrigo Cartin-Ceba2 and Ulrich Specks1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Scottsdale, AZ

    Background/Purpose: We aimed to investigate the relationship between hydralazine and any form of vasculitis (small, medium, or large vessel), to describe clinical features and outcomes…
  • Abstract Number: 0237 • ACR Convergence 2024

    Tofacitinib: A Retrospective Study on Safety and Adverse Effects

    Vrushal Kale1, Sandeep yadav2, Canchi Balakrishnan3, Rohini Samant4, Bishakha Swain4, Shaurav Khanna5, Aashish Agrawal5 and Aditi Patankar4, 1P D Hinduja national Hospital and medical Research centre, Mumbai, Maharashtra, India, 2Pd Hinduja hospital, Thane, Maharashtra, India, 3P D Hinduja Hospital and Medical Research Centre, Mahim, Mumbai, Mahin, Maharashtra, India, 4P D Hinduja Hospital and Medical Research Centre, Mumbai, mumbai, Maharashtra, India, 5P D Hinduja Hospital and Medical Research Centre, Mahim, Mumbai, Mumbai, Maharashtra, India

    Background/Purpose: Tofacitinib, an oral Janus kinase inhibitor, is widely used in India to treat rheumatoid arthritis (RA) and other autoimmune diseases. Although its efficacy is…
  • Abstract Number: 1208 • ACR Convergence 2024

    Statin Use and Risk of Total Joint Replacement of Knee and Hip in Osteoarthritis Patients: Study Based on the French National Health Insurance Cohort

    christian roux1, stephanie ferrero2, Julie Bulsai2 and eric fontas2, 1rheumatology department, university Cote d'Azur, nice, France, 2university cote d'azur, CHU de Nice, nice, France

    Background/Purpose: Potential beneficial effect of statin use on osteoarthritis progression is discussed. some studies have suggested that statins may have a protective effect on structural…
  • Abstract Number: 2497 • ACR Convergence 2024

    Clinical Characteristics and Outcomes of Hydralazine-induced ANCA-associated Vasculitis. a Single Center Retrospective Cohort Analysis from the US

    Muhammad Shamim1, Mazen Allouni2, Haseeb Chaudhary3, Ansaam Daoud4, Loai Dweik5, Hashim Syed6 and Omer Pamuk7, 1University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, 2Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, 3Case Western Reserve University, Westlake, OH, 4Case Western Reserve University/University Hospitals, Akron, OH, 5Cleveland Clinic Akron General Internal Medicine, Akron, OH, 6Case Western/ UH, Cleveland, 7University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH

    Background/Purpose: Hydralazine-induced ANCA-associated vasculitis (HIAAV) is a rare clinical problem.  There is paucity of data regarding clinical features, treatment, and prognosis of hydralazine-induced AAV in…
  • Abstract Number: 0252 • ACR Convergence 2024

    Prospective Study of Severe Infectious Events and Immune Reconstitution After Rituximab in Autoimmune Diseases

    Aurélien Chepy1, Michaël Genin2, Louis Terriou3, Cécile Chenivesse4, Delphine Staumont-Sallé5, Hélène Zéphir6, Peggy philippe7, Guillaume Lefevre8, Sarah Stabler9, Eric HACHULLA3, David Launay10 and Vincent Sobanski3, 1Univ. Lille, Inserm, CHU Lille, U1286—INFINITE—Institute for Translational Research in Inflammation, Lille, France., Lille, Nord-Pas-de-Calais, France, 2Univ. Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, Lille, F-59000, France., Lille, France, 3CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., Lille, France, 4Centre de Référence Constitutif des Maladies Pulmonaires Rares, CHU Lille, Service de Pneumologie et Immuno-Allergologie, Lille 59000, France., Lille, France, 5Service de dermatologie CHU Lille Université de Lille Lille France., Lille, France, 6Department of Neurology, CRC-SEP, CHU of Lille, Lille, France., Lille, France, 7Rheumatology Department, Lille University Hospital, Lille, France., Lille, France, 8CHU Lille, Institut d’Immunologie, Lille, France., Lille, France, 9CHU Lille, Service Universitaire de Maladies Infectieuses, F-59000 Lille, France; Univ. Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Lille, France, 10CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., Lille Cedex, France

    Background/Purpose: Rituximab (RTX) administration in autoimmune diseases (AID) is associated with severe infectious events (SIE). Frequency of SIE and immune reconstitution (B cells, T cells,…
  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology